Antiviral compounds
Inventors
Yu, Jianming • LI, XIBEN • Leon, Robert • Szymaniak, Adam • Kim, In Jong • Or, Yat Sun
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12162857-B2
Publication Date
2024-12-10
Expiration Date
Abstract
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Core Innovation
The invention relates to a compound represented by Formula (V-3), or a pharmaceutically acceptable salt thereof. The compound is defined by selections of substituents for R4, R7, R6, R11 and R12, R21, R23, R24, R31 and R32, and n, with allowed groups including optionally substituted alkyl, cycloalkyl, heterocyclic, aryl, arylalkyl, heteroaryl, and heteroarylalkyl substituents, together with hydrogen, halogen, alkoxy, cyano, and amino-related options.
The compound definition further includes carboxamide forms and the possibility that R11 and R12 are taken together with the nitrogen atom to form an optionally substituted heterocyclic ring. The disclosed scope also covers variants in which R21, R23, and R24 occupy further substitution positions, and n is 1, 2, 3, 4 or 5. The patent describes these compounds as a defined chemical family with constrained substituent choices across the Formula (V-3) scaffold.
The disclosed embodiments also situate these compounds within pharmaceutical use contexts directed to respiratory virus infections. The partial content states treatment or prevention of respiratory syncytial virus (RSV) infection, human metapneumovirus (HMPV) infection, and RSV infection and influenza, including combination with an anti-influenza agent and embodiments in which the compound and an anti-HMPV agent are co-formulated or co-administered.
Claims Coverage
The provided claims center on 1 independent claim directed to a Formula (V-3) compound or pharmaceutically acceptable salt thereof. The independent inventive features are the specified structural definitions for R4, R7, R6, R11/R12, R21/R23/R24/R31/R32, and n, with dependent claim coverage tied to viral infection indications and combination therapy contexts.
Formula (V-3) compound with constrained substituent selections
A compound represented by Formula (V-3), or a pharmaceutically acceptable salt thereof, wherein R4 is selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; R7 is selected from hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, and optionally substituted C3-C8 cycloalkyl; and R6 is selected from C(O)NH2, optionally substituted C1-C8-alkyl, optionally substituted C3-C8-cycloalkyl, hydrogen, optionally substituted 4- and 5-membered heterocyclic ring, C(O)NHR11, and C(O)NR11R12.
Variable side-group definitions for R11/R12 and R21/R23/R24/R31/R32
R11 and R12 are each independently selected from optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3- to 8-membered heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroalkyl, or are taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocyclic ring; each R21 is independently optionally substituted methyl, halo, CN, OR31, or NR31R32; R23 is hydrogen, halo, OR31, optionally substituted C1-C6 alkyl, or optionally substituted C3-C8 cycloalkyl; R24 is optionally substituted C1-C6 alkyl or optionally substituted C3-C8 cycloalkyl; and each R31 and R32 is independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 4- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroalkyl.
Indexing parameter n for the Formula (V-3) compound
The compound of Formula (V-3) is defined such that n is 1, 2, 3, 4 or 5.
Therapeutic use for RSV infection
A method for treating or preventing a respiratory syncytial virus (RSV) infection in a subject by administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
Therapeutic use for HMPV infection
A method for treating or preventing a human metapneumovirus (HMPV) infection in a subject by administering a therapeutically effective amount of the compound of claim 1.
RSV infection and influenza treatment with an anti-influenza agent
A method for treating RSV infection and influenza in a subject by administering a therapeutically effective amount of a compound of claim 1 together with a therapeutically effective amount of an anti-influenza agent.
Co-formulation or co-administration with an anti-HMPV agent
A method in which the compound and an anti-HMPV agent are co-formulated or co-administered.
Coverage centers on a Formula (V-3) compound family defined by explicit substituent selections for R4, R7, R6, R11/R12, R21/R23/R24/R31/R32, and n, with dependent claims directed to RSV and HMPV treatment, RSV plus influenza treatment with an anti-influenza agent, and co-formulation or co-administration with an anti-HMPV agent.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating or preventing a respiratory syncytial virus (RSV) infection in a subject by administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
Treating or preventing a human metapneumovirus (HMPV) infection in a subject by administering a therapeutically effective amount of the compound of claim 1.
Treating RSV infection and influenza in a subject by administering a therapeutically effective amount of a compound of claim 1 together with a therapeutically effective amount of an anti-influenza agent.
Co-formulating the compound with an anti-HMPV agent.
Co-administering the compound together with an anti-HMPV agent.
Antiviral activity against RSV-A in Hep-2 cells.
Antiviral activity against HMPV in LLC-MK2 cells.
Interested in licensing this patent?